Intracranial delivery of recombinant nerve growth factor: Release kinetics and protein distribution for three delivery systems

Pharmaceutical Research

Volumn 16, Issue 2, 1999, Pages 232-240

  Saltzman, W Mark ^a   Mak, Michele W ^b   Mahoney, Melissa J ^a   Duenas, Eileen T ^c   Cleland, Jeffrey L ^c  

^a Cornell University   (United States)

^b Johns Hopkins University   (United States)

^c GENENTECH INC   (United States)

Author keywords

Controlled release; Drug delivery; Microspheres; Neurotrophin; Poly(lactide co glycolide)

Indexed keywords

ETHYLENE VINYL ACETATE COPOLYMER; MICROSPHERE; NERVE GROWTH FACTOR; POLYGLACTIN; RECOMBINANT NERVE GROWTH FACTOR;

ANIMAL TISSUE; ARTICLE; BRAIN SLICE; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FREEZE DRYING; INTERMETHOD COMPARISON; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; NONHUMAN; PELLET EXTRUSION; PHARMACEUTICAL ENGINEERING; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN SECRETION; RAT; TISSUE DISTRIBUTION;

EID: 0033049490     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1018824324275     Document Type: Article

References (31)

1. 1. R. M. Lindsay, S. J. Wiegand, C. A. Altar, and P. S. DiStefano. Neurotrophic factors: from molecule to man. TINS 17:182-190 (1994).
2. 2. W. M. Saltzman. Growth factor delivery in tissue engineering. MRS Bulletin 21:62-65 (1996).
3. 3. M. J. Mahoney and W. M. Saltzman. Controlled release of proteins to tissue transplants for the treatment of neurodegenerative disorders. J. Pharm. Sci. 85:1276-1281 (1996).
4. 4. E. M. Powell, M. R. Sobarzo, and W. M. Saltzman. Controlled release of nerve growth factor from a polymeric implant. Brain Res. 515:309-311 (1990).
5. 5. C. E. Krewson and W. M. Saltzman. Nerve growth factor delivery and cell aggregation enhance choline acetyltransferase activity after neural transplantation. Tissue Eng. 2:183-196 (1996).
6. 6. C. E. Krewson and W. M. Saltzman. Transport and elimination of recombinant human NGF during long-term delivery to the brain. Brain Res. 727:169-181 (1996).
7. 7. C. E. Krewson, M. Klarman, and W. M. Saltzman. Distribution of nerve growth factor following direct delivery to brain interstitium. Brain Res. 680:196-206 (1995).
8. 8. P. J. Camarata, R. Suryanarayanan, D. A. Turner, R. G. Parker, and T. J. Ebner. Sustained release of nerve growth factor from biodegradable polymer microspheres. Neurosurgery 30:313-319 (1992).
9. 9. D. Maysinger, J. Filipovic-Grcic, and A. C. Cuello. Effects of coencapsulaed NGF and GM 1 in rats with cortical lesions. NeuroReport 4:971-974 (1993).
10. 10. S. Yamamoto, Y. T., T. Fujita, R. Kuroda, T. Irie, K. Fujioka, and T. Hayakawa. Protective effect of NGF atelocollagen mini-pellet on the hippocampal delayed neuronal death in gerbils. Neurosci. Letters 141:161-165 (1992).
11. 11. W. M. Saltzman and M. L. Radomsky. Drugs released from polymers: diffusion and elimination in brain tissue. Chem. Eng. Sci. 46:2429-2444 (1991).
12. 12. T. Heya, H. Okada, Y. Ogawa, and H. Toguchi. In vitro and in vivo evaluation ofthyrotrophin releasing hormone release from copoly(dl-lactic/glycolic acid) microspheres. J. Pharm. Sci. 83:636-640 (1994).
13. 13. P. A. Lapchak, D. M. Araujo, S. Carswell, and F. Hefti. Distribution of [125I] nerve growth factor in the rat brain following a single intraventricular injection: correlation with the topographical distribution oftrk A messenger RNA-expressing cells. Neuroscience 54:445-460 (1993).
14. 14. K. D. Anderson, R. F. Alderson, C. A. Altar, P. S. Distefano, T. L. Corcoran, R. M. Lindsay, and S. J. Wiegand. Differential distribution of exogenous BDNF, NGF,and NT-3 in the brain corresponds to the relative abundance and distribution of high affinity and low-affinity neurotrophin receptors. J. Comp. Neurol. 357:296-317 (1995).
15. 15. M. H. Tuszynski, H. S. U, K. Yoshida, and F. H. Gage. Recombinant human nerve growth factor infusions prevent cholinergic neuronal degeneration in the adult primate brain. Ann. Neurol. 30:625-636 (1991).
16. 16. C. E. Krewson, R. B. Dause, M. W. Mak, and W. M. Saltzman. Stabilization of nerve growth factor in polymers and in tissues. J. Biomat. Sci. Polym. Ed. 8:103-117 (1996).
17. 17. D. Maysinger, I. Jalsenjak, and A. C. Cuello. Microencapsulated nerve growth factor: effects on the forerain neurons following devascularizing cortical lesions. Neurosci. Letters 140:71-74 (1992).
18. 18. C. E. Beaty and W. M. Saltzman. Controlled growth factor delivery induces differental neurite outgrowth in three-dimensional cell cultures. J. Contr. Rel. 24:15-23 (1993).
19. 19. O. L. Johnson, J. L. Cleland, H. J. Lee, M. Chamis, E. Duenas, W. Jaworowicz, D. Shepard, A. Shahzamani, A. J. S. Jones, and S. D. Putney. A month-long effect from a single injection of microencapsulated human growth hormone. Nature Med. 2:795-798 (1996).
20. 20. L. K. Fung. M. G. Ewend, A. Sills, E. P. Sipos, R. Thompson, M. Watts, O. M. Colvin, H. Brem, and W. M. Saltzman. Pharmacokinetics of interstitial delivery of carmustine, 4-hydroperoxycyclophosphamide, and paclitaxel from a biodegradable polymer implant in the monkey brain. Canc. Res. 58:672-684 (1998).
21. 21. R. Loy, G. Taglialatela, L. Angelucci, D. Heyer, and R. Perez-Polo. Regional CNS uptake of blood-borne nerve growth factor. J. Neurosci. 39:339-346 (1994).
22. 22. J. F. Poduslo, G. L. Curran, and C. T. Berg. Macromolecular permeability across the blood-nerve and blood-brain barriers. Proc. Natl. Acad. Sci. USA 91:5705-5709 (1994).
23. 23. S. Yamada, M. DePasquale, C. S. Patlak, and H. F. Cserr. Albumin outflow into deep cervical lymph from different regions of rabbit brain. Am. J. Physiol. 261:H1197-H1204 (1991).
24. 24. H. F. Cserr and P. M. Knopf. Cervical lymphatics, the blood-brain barrier and the immunoreactivity of the brain. Immunology Today 13:507-512 (1992).
25. 25. U. Otten and R. A. Gadient. Neurotrophins and cytokines-intermediaries between the immune and nervous systems. Int. J. Dev. Neurosci. 13:147-151 (1995).
26. 26. B. G. Petty, D. R. Cornblath, B. T. Adornato, V. Chaudhry, C. Flexner, M. Wachsman, D. Sinicropi, L. E. Burton, and S. J. Peroutka. The effect of systemically administered recombinant human nerve growth factor in healthy human subjects. Ann. Neurol. 36:244-246 (1994).
27. 27. B. Knusel, D. R. Kaplan, and F. Hefti. Intraparenchymal NGF injections in adult and aged rats induce long-lasting TRK Tyrosine phosphorylation. Exp. Neurol. 139:121-130 (1996).
28. 28. T. Naumann, P. Kermer, V. Seydewitz, R. Ortmann, F. D'Amato, and M. Frotscher. Is there a long-lasting effect of short-term nerve growth factor application on axotomized rat septohippocampal neurons? Neurosci. Letters 173:213-215 (1994).
29. 29. V. E. Koliatsos, B. S. Clatterbuck, G. J. W. Nauta, B. Knusel, L. E. Burton, F. F. Hefti, W. C. Mobley, and D. L. Price. Human nerve growth factor prevents degeneration of basal forebrain cholinergic neurons in primates. Ann. Neurol. 30:831-840 (1991).
30. 30. M. H. Tuszynski, H. S. U, K. Yoshida, and F. H. Gage. Recombinant human nerve growth factor infusions prevent cholinergic neuronal degeneration in the adult primate brain. Ann. Neurol. 30:625-36 (1991).
31. 31. A. Lambiase, P. Rama, S. Bonini, G. Caprioglio, and L. Aloe. Topical treatment with nerve growth factor for corneal neurotrophic ulcers. N. Engl. J. Med. 338:1174-1180 (1998).